CTRI/2013/04/003538招募中3 期
A Multi-Center, Double Blind, Placebo-Controlled, Randomized, Parallel-GroupStudy To Evaluate The Safety And Clinical Equivalence of a Generic SucralfateOral Suspension, 1g/10ml (Hi-Tech Pharmacal Co., Inc., USA) To Carafate®Suspension, 1g/10ml (Aptalis Pharma, Inc., [Formerly Axcan Pharma US, Inc.,USA]) in the Treatment of Active Duodenal Ulcer Disease
HiTech Pharmacal Co Inc0 个研究点目标入组 575 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 575
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Patient must have endoscopically confirmed active duodenal ulcer of at least 3 mm in
- •diameter and not exceeding 25 mm. 2. Patients must be confirmed H.pylori negative. 3. Willingness to continue with current (baseline) behavior with respect to diet, smoking, alcohol and caffeine consumption throughout the study.
- •4. Patient must sign an IRB/IEC-approved written Informed Consent Form (ICF), which
- •includes agreement to comply with all study requirements as indicated in the protocol,
- •including a negative urine pregnancy test at time of entry (if a female of child-bearing
- •potential).
排除标准
- •1. Regular use of therapeutic dose of any non-steroidal anti-inflammatory drug (NSAID)
- •during the study period or within 8 weeks prior to the baseline endoscopy.
- •2. Presence of 1 or more chronic ulcers. 3. Patients with more than two duodenal ulcers.
- •4. Patients with antral, pre-pyloric (more than 1 cm proximal to the pyloric channel) or post-bulbar lesions despite possible concomitant lesions in the duodenum.
- •5. Patients whose ulcer is due to other diseases (e.g. Zollinger-Ellison Syndrome).
- •6. Patients with esophageal or gastric ulcers, or with active bleeding.
- •7. Patients being treated with an H2 receptor antagonist, prostaglandin, antacids, proton pump inhibitors, or any other anti-ulcer medication.
- •8. Requirement for continuing treatment with tetracyclines, or antimicrobial agents.
- •9. Use of any investigational agent within 30 days of the first dose of study medication.
- •10. Patients who have undergone previous gastric surgery, or who have previously
- •experienced a perforated ulcer.
- •11. Co-existent pyloric stenosis, gastric outlet obstruction, or grade II or III esophagitis.
- •12. Bleeding ulcer or a history of a bleeding ulcer within 1 year prior to enrollment.
- •13. Presence of malignant lesions.
- •14. Significant and uncontrolled hepatic, cardiac, renal, or endocrine dysfunction.
- •15. A baseline serum aluminum concentration above upper limit of the normal range in the
- •presence of abnormal renal function or an
- •aluminum concentration at baseline that is greater than 2.5 times the upper limit of the
- •normal range in a patient with normal renal function.
- •16. Patients who have undergone major trauma or surgery within the previous four weeks or
- •patients scheduled to undergo surgery during the period of time covered by the study.
- •17. History of alcoholism or drug abuse in the 2 years prior to the study.
- •18. Any significant medical disorder that in the opinion of investigator, would preclude
- •accurate evaluation of the patientâ??s condition.
- •19. Females who are pregnant or lactating or planning pregnancy during the study.
研究者
相似试验
进行中（未招募）
不适用
A Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Safety Study ofPulmonary Function in Patients with Reduced Lung Function Treated with BOTOX®(Botulinum Toxin Type A) Purified Neurotoxin Complex for Focal Upper LimbSpasticity Due to Upper Motor Neuron SyndromeEUCTR2005-004834-42-HUAllergan150
进行中（未招募）
不适用
A Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Safety Study ofPulmonary Function in Patients with Reduced Lung Function Treated with BOTOX®(Botulinum Toxin Type A) Purified Neurotoxin Complex for Focal Upper LimbSpasticity Due to Upper Motor Neuron SyndromeFocal upper limb spasticity due to upper motor neuron syndromeincluding poststroke spasticity. (for the objective of this study patients must also have stable compromised baseline respiratory status)MedDRA version: 8.1Level: PTClassification code 10028335EUCTR2005-004834-42-CZAllergan150
招募中
2 期
To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes TherapiesCTRI/2010/091/000151ovartis Healthcare Private Limited244
进行中（未招募）
不适用
A Multi-Centre, Double-Blind, Placebo-Controlled, Parallel-Group Induction-Design Study to assess the Clinical Effect of Droxidopa in Subjects with Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic Neurogenic Orthostatic HypotensioEUCTR2008-002855-26-ATChelsea Therapeutics Inc176
进行中（未招募）
不适用
A Multi-Centre, Double-Blind, Placebo-Controlled, Ascending-Dose, Clinical Trial of Intra-venous Microplasmin Administration in Patients with Acute Ischemic Stroke - MITI-IVEUCTR2005-001074-27-BEThromboGenics Ltd.40